Two 65-year-old white men with coronary heart disease, given niacin (a) (Lp[a] ).2'3 In patients with coro¬ nary heart disease its use has been associated with lack of progression or actual regression of coronary plaques4 and a reduction in all-cause mortality.5'6
= lipoprotein (a) Niacin has long been recognized to be a useful lipidlowering drug. It is the most effective drug for raising high-density (HDL) lipoprotein cholesterol1 and the only lipid-lowering drug that has been shown to lower serum levels of lipoprotein (a) (Lp[a] ).2'3 In patients with coro¬ nary heart disease its use has been associated with lack of progression or actual regression of coronary plaques4 and a reduction in all-cause mortality.5 '6 The usual dose of niacin recommended for lowering lipid is 1.5 to 6 g daily, but because of side effects, few patients can take the larger dose. The side effects of niacin are well known and have been described in detail.1-7 The most consistent side effect is cutaneous flushing and the most serious side effect is hepatitis. In long-term studies, the incidence of discontinuing the drug due to side effects 4.65 (180) 4.68 (181) 3.62 (140) 1.08 (96) 1.34 (119) 1.13 (100) 1.20 (106) (Fig 2) . The walls of the bullae contained little fibrosis and rare noncaseating granulomas. Polarized 
